GlobeStar Therapeutics Corporation GSTC
0.00 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.0001 Day range 0.0001
0.0001 52-week range 0.0001
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 124.11K
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 300.00K
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0001
2Y -0.0003 (-75.00%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 11, 2024 | Jun 1, 2024 | 0.00 | 0.00 | — | — |
| Jun 28, 2024 | Mar 1, 2024 | 0.00 | 0.00 | — | — |
| Mar 11, 2024 | Dec 1, 2023 | 0.00 | 0.00 | — | — |
| Jan 19, 2024 | Sep 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 17, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
| May 31, 2023 | Mar 1, 2023 | 0.00 | 0.00 | — | — |
News
Globestar Therapeutics Update on Project Amethyst(TM) and Recent Financials 
GlobeStar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies and Strategies for Multiple Sclerosis Treatment 
Globestar Therapeutics Enters into Definitive Agreement with SMI Healthcare to Manage Clinical Trial, Regulatory Filings, Manufacturing and Sales in MEA Region for Multiple Sclerosis Treatment 
GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets 
GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial. 
GlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple Sclerosis 
GlobeStar Therapeutics Corporation Unveils New Corporate Website and Branding Campaign 
GlobeStar Therapeutics Corporation To Be Seen In The Washington Football Team Yearbook All Season
Your note
Sign in to keep a note on GSTC — it syncs with the Stock Master app.